148 related articles for article (PubMed ID: 31321907)
1. Issue Highlights - July 2019.
Cytometry B Clin Cytom; 2019 Jul; 96(4):253-255. PubMed ID: 31321907
[No Abstract] [Full Text] [Related]
2. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
[No Abstract] [Full Text] [Related]
3. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.
Ok CY; Leventaki V; Wang SA; Dinardo C; Medeiros LJ; Konoplev S
Am J Clin Pathol; 2016 Feb; 145(2):271-6. PubMed ID: 26800764
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of Flow Cytometry for the Detection of Cutaneous Localization in Malignant Hematologic Disorders.
Maitre E; Le-Page AL; Comoz F; Truquet F; Damaj G; Cornet E; Verneuil L; Salaün V; Troussard X
Cytometry B Clin Cytom; 2019 Jul; 96(4):283-293. PubMed ID: 31050147
[TBL] [Abstract][Full Text] [Related]
5. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.
Iurlo A; Gianelli U; Cattaneo D; Thiele J; Orazi A
Am J Hematol; 2017 Apr; 92(4):E48-E51. PubMed ID: 28109016
[No Abstract] [Full Text] [Related]
6. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
Struski S; Luquet I
Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
[No Abstract] [Full Text] [Related]
7. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
8. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
[No Abstract] [Full Text] [Related]
9. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
10. Meningeal spread of blastic plasmacytoid dendritic cell neoplasm.
Starck M; Zewen S; Eigler A; Wendtner CM
Eur J Haematol; 2014 Aug; 93(2):175-6. PubMed ID: 24483771
[No Abstract] [Full Text] [Related]
11. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.
Bench AJ; Erber WN; Scott MA
Clin Lab Haematol; 2005 Jun; 27(3):148-71. PubMed ID: 15938721
[TBL] [Abstract][Full Text] [Related]
12. α-Hemoglobin-stabilizing Protein: An Effective Marker for Erythroid Precursors in Bone Marrow Biopsy Specimens.
Yu H; Pinkus JL; Pinkus GS
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):51-6. PubMed ID: 25611244
[TBL] [Abstract][Full Text] [Related]
13. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders.
Wood BL
J Biol Regul Homeost Agents; 2004; 18(2):141-5. PubMed ID: 15471218
[TBL] [Abstract][Full Text] [Related]
15. [Flow cytometric cell analysis by surface antigen according to CD grouping].
Tsuruda K; Hamasaki N; Matsuno T; Moriuchi T; Atogami S; Kamihira S
Nihon Rinsho; 2010 Jun; 68 Suppl 6():847-54. PubMed ID: 20942203
[No Abstract] [Full Text] [Related]
16. Deletion of Ptpn1 induces myeloproliferative neoplasm.
Jobe F; Patel B; Kuzmanovic T; Makishima H; Yang Y; Przychodzen B; Hutchison RE; Bence KK; Maciejewski JP; Mohi G
Leukemia; 2017 May; 31(5):1229-1234. PubMed ID: 28111468
[No Abstract] [Full Text] [Related]
17. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
Northrup V; Maybank A; Carson N; Rahmeh T
Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
[TBL] [Abstract][Full Text] [Related]
18. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
19. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
20. A relational database for diagnosis of hematopoietic neoplasms using immunophenotyping by flow cytometry.
Nguyen AN; Milam JD; Johnson KA; Banez EI
Am J Clin Pathol; 2000 Jan; 113(1):95-106. PubMed ID: 10631862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
